Newsroom press releases

17/12/24 - 12:56

2025 Annual Calendar of Corporate Events (104.79 KB)

Download

11/11/24 - 7:38

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)

Products Molecular

Download

05/11/24 - 16:27

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)

Financial Data

Download

27/09/24 - 7:35

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)

Products Molecular

Download

09/09/24 - 13:11

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)

Products Immunodiagnostic

Download

05/09/24 - 11:17

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)

Other

Download

04/09/24 - 11:36

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)

Other

Download

29/07/24 - 15:55

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)

Financial Data

Download

16/07/24 - 8:31

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)

Products Molecular

Download

05/06/24 - 5:07

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)

Products Molecular

Download

16/05/24 - 19:56

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)

Products Molecular

Download

10/05/24 - 15:21

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)

Financial Data

Download

24/04/24 - 15:38

Shareholders' Meeting 2024 (159.72 KB)

Other

Download

16/04/24 - 8:20

Communication on total amount of voting rights (135.47 KB)

Other

Download

15/03/24 - 13:35

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)

Financial Data

Download

13/03/24 - 10:23

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)

Products Molecular

Download

03/03/24 - 19:32

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)

Products Molecular

Download

25/01/24 - 7:48

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)

Products Immunodiagnostic

Download

23/12/11 - 1:00

Financial instruments to employees (57.22 KB)

Financial Data

Download

19/12/11 - 1:00

Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only) (192.66 KB)

Products Immunodiagnostic

Download

19/11/11 - 1:00

Buy-back plan (35.47 KB)

Financial Data

Download

18/11/11 - 1:00

Financial instruments to employees (56.82 KB)

Financial Data

Download

11/11/11 - 1:00

The BoD approves Q3'11 results (334.35 KB)

Financial Data

Download

28/10/11 - 2:00

Buy-back plan (103.99 KB)

Financial Data

Download

25/10/11 - 2:00

Buy-back plan (104.72 KB)

Financial Data

Download

18/10/11 - 2:00

Buy-back plan (136.18 KB)

Financial Data

Download

17/10/11 - 2:00

2011-2015 Business Plan: a new business wave (195.1 KB)

Financial Data

Download

10/10/11 - 2:00

New Chief Financial Officer (196.26 KB)

Other

Download

06/10/11 - 2:00

Cardinal Health: agreement extended to 2014 (192.57 KB)

Acquisition / Partnership

Download

04/10/11 - 2:00

Buy-back plan (204.92 KB)

Financial Data

Download

01/09/11 - 2:00

Resignation of Chief Financial Officer (177.77 KB)

Other

Download

31/08/11 - 2:00

2011 Financial calendar update (176.4 KB)

Financial Data

Download

03/08/11 - 2:00

The BoD approves H1'11 results (324.48 KB)

Financial Data

Download

11/07/11 - 2:00

Voluntarily removal from the STAR segment (194.93 KB)

Financial Data

Download

13/05/11 - 2:00

The BoD approves Q1'11 results (307.28 KB)

Financial Data

Download

11/05/11 - 2:00

DiaSorin and Labcorp extend strategic business relationship (100.01 KB)

Acquisition / Partnership

Download

06/05/11 - 2:00

Agreement with Precision System Science Co., LTD (171.54 KB)

Acquisition / Partnership

Download

28/04/11 - 2:00

The Ordinary Shareholders' meeting approves the 2010 statutory financial statements and the dividend distribution (175.61 KB)

Financial Data

Download

16/03/11 - 1:00

The BoD approves FY'10 results (368.28 KB)

Financial Data

Download

16/03/11 - 1:00

Dividend information amendment (159.83 KB)

Financial Data

Download

28/02/11 - 1:00

2011 Financial calendar update (179.92 KB)

Financial Data

Download

19/02/11 - 1:00

Notice of change in share capital (5.28 KB)

Financial Data

Download

18/02/11 - 1:00

Buy-back plan (134.06 KB)

Financial Data

Download

17/02/11 - 1:00

Financial instruments to employees (56.37 KB)

Financial Data

Download

16/02/11 - 1:00

Buy-back plan (105.2 KB)

Financial Data

Download

15/02/11 - 1:00

Buy-back plan (91.38 KB)

Financial Data

Download

14/02/11 - 1:00

The BoD approves Q4'10 results (161 KB)

Financial Data

Download

31/01/11 - 1:00

Buy-back plan (105.05 KB)

Financial Data

Download

29/01/11 - 1:00

Buy-back plan (105.2 KB)

Financial Data

Download

28/01/11 - 1:00

Buy-back plan (105.04 KB)

Financial Data

Download

27/01/11 - 1:00

Buy-back plan (105.04 KB)

Financial Data

Download

26/01/11 - 1:00

FDA approves the LIAISON XL (194.2 KB)

Products Immunodiagnostic

Download

25/01/11 - 1:00

Buy-back plan (105.22 KB)

Financial Data

Download

24/01/11 - 1:00

Buy-back plan (104.72 KB)

Financial Data

Download

21/01/11 - 1:00

Buy-back plan (105.05 KB)

Financial Data

Download

20/01/11 - 1:00

Buy-back plan (91.39 KB)

Financial Data

Download

19/01/11 - 1:00

Buy-back plan (105.31 KB)

Financial Data

Download

18/01/11 - 1:00

Buy-back plan (35.47 KB)

Financial Data

Download

17/01/11 - 1:00

Buy-back plan (134.01 KB)

Financial Data

Download

17/01/11 - 1:00

The Sonic Healthcare Group chooses DiaSorin (181.71 KB)

Acquisition / Partnership

Download

16/01/11 - 1:00

2011 Financial calendar (179.49 KB)

Financial Data

Download

Newsroom press releases

Select year

Newsroom press category

2025 Annual Calendar of Corporate Events (104.79 KB)

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)

Shareholders' Meeting 2024 (159.72 KB)

Communication on total amount of voting rights (135.47 KB)

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)

Financial instruments to employees (57.22 KB)

Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only) (192.66 KB)

Buy-back plan (35.47 KB)

Financial instruments to employees (56.82 KB)

The BoD approves Q3'11 results (334.35 KB)

Buy-back plan (103.99 KB)

Buy-back plan (104.72 KB)

Buy-back plan (136.18 KB)

2011-2015 Business Plan: a new business wave (195.1 KB)

New Chief Financial Officer (196.26 KB)

Cardinal Health: agreement extended to 2014 (192.57 KB)

Buy-back plan (204.92 KB)

Resignation of Chief Financial Officer (177.77 KB)

2011 Financial calendar update (176.4 KB)

The BoD approves H1'11 results (324.48 KB)

Voluntarily removal from the STAR segment (194.93 KB)

The BoD approves Q1'11 results (307.28 KB)

DiaSorin and Labcorp extend strategic business relationship (100.01 KB)

Agreement with Precision System Science Co., LTD (171.54 KB)

The Ordinary Shareholders' meeting approves the 2010 statutory financial statements and the dividend distribution (175.61 KB)

The BoD approves FY'10 results (368.28 KB)

Dividend information amendment (159.83 KB)

2011 Financial calendar update (179.92 KB)

Notice of change in share capital (5.28 KB)

Buy-back plan (134.06 KB)

Financial instruments to employees (56.37 KB)

Buy-back plan (105.2 KB)

Buy-back plan (91.38 KB)

The BoD approves Q4'10 results (161 KB)

Buy-back plan (105.05 KB)

Buy-back plan (105.2 KB)

Buy-back plan (105.04 KB)

Buy-back plan (105.04 KB)

FDA approves the LIAISON XL (194.2 KB)

Buy-back plan (105.22 KB)

Buy-back plan (104.72 KB)

Buy-back plan (105.05 KB)

Buy-back plan (91.39 KB)

Buy-back plan (105.31 KB)

Buy-back plan (35.47 KB)

Buy-back plan (134.01 KB)

The Sonic Healthcare Group chooses DiaSorin (181.71 KB)

2011 Financial calendar (179.49 KB)

Price Sensitive